Score Your Stock

US stock · figures in US dollars · scored on full-year results

Revvity Revvity, Inc. Common Stock

RVTY · Healthcare · Diagnostics & Research
Top 50% of scored stocks
OkayTop 50% of scored stocks
Weak Spot

Revvity scores 54/100 on fundamentals: in the top 50% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (83/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 83
Weakest
Price 0
  • Carries a Weak Spot flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 17.5b#429 of 503 in the S&P 500EPSUS$ 2.09P/E73.8×✗ vs sector median 29.6×P/B2.4×✓ vs sector median 4×Div yield0%Bottom 22% in the S&P 50052w range · 86% of range81.22169.06
as of 31 Oct 2026

Nearby peers

Ranks #31 of 60 in Healthcare by score

#1Universal Health Services79#29HCA Healthcare54#30Regeneron Pharmaceuticals54
#31Revvity54
#32Biogen53#33Cencora53

One-Minute Summary

Why Revvity scores 54

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

30
Why 30?
Pillar score: (0 + 1 + 0 + 1 + 1) = 3 of 10 points → 30
Return on Equity (ROE)3%Weak4-Year Revenue Growth+2%/yrOkay4-Year Profit Growth-30%/yrWeakNet Profit Margin8%OkayQuarterly Momentum+5%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -65.7%Equity ↓ -8.2%ROE % 3.3%
Net ProfitEquityROE %
693m270m241m238m7.9b7.7b7.3b7.2b202320242025TTM8.8%3.5%3.3%3.3%

Revenue & Net Profit, with Net Margin

Revenue ↑ +5.9%Net Profit ↓ -65.7%Net Margin % 8.2%
RevenueNet ProfitNet Margin %
2.8b2.8b2.9b2.9b693m270m241m238m202320242025TTM25.2%9.8%8.4%8.2%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

Profit fell about 65.7% from where it was 4 years ago: the boom has cooled off.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue → +0%Net Profit ↓ -45.2%Net Margin % 7.1%
RevenueNet ProfitNet Margin %
729m665m720m699m772m711m730m730m95m42m54m47m98m41m52m52mQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'2613%6.3%7.5%6.7%12.7%5.7%7.1%7.1%
▲▲▬▼▬▬▬▲

Sales have stayed roughly flat over the last 8 quarters.

Profit fell about 45.2% over the last 8 quarters.

Why 83?
Pillar score: (2 + 2 + 1) = 5 of 6 points → 83
Debt-to-Equity0.5×StrongCurrent Ratio1.8×StrongInterest Coverage3.6×Okay
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -17.8%Equity ↓ -8.2%D/E 0.5×
Total DebtEquityD/E
4.1b3.3b3.4b3.3b7.9b7.7b7.3b7.2b202320242025TTM0.5×0.4×0.5×0.5×

Borrowings fell about 17.8% over 4 years: the company is steadily getting safer.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -23.4%Current Liabilities ↓ -12%Current Ratio 1.8×
Current AssetsCurrent LiabilitiesCurrent Ratio
3.0b2.3b2.2b2.3b1.5b653m1.3b1.3b202320242025TTM2.1×3.6×1.7×1.8×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend Quality0%Weak
Payout ratio: 13%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +587.4%Free CF ↑ +5,537.4%
Operating CFFree CF
91m628m583m628m10m542m509m558m202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +12%Short-Term Debt ↓ -20.7%Total Debt ↓ -17.8%
CashShort-Term DebtTotal Debt
913m1.2b920m1.0b722m0m589m572m4.1b3.3b3.4b3.3b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0.2%
DPS (cents)Yield %
77777777772828282820222023202420250.2%0.2%0.3%0.2%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio73.8×WeakP/B Ratio2.4×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 158.77US$ 121.26US$ 83.75Oct '25Feb '26Jun '26Oct '26

The share price is up about 68.2% over the past year.

Why 75?
Pillar score: (0 + 2 + 2 + 2 + 2 + 1) = 9 of 12 points → 75
Earnings ConsistencyVery bumpyWeakDebt Trend (4yr)FallingStrongShare Count Trend (4yr)-3%/yrStrongInventory vs Sales (4yr)-5.9 pp/yr vs salesStrongAsset Turnover Trend (4yr)+19.2%StrongQuarterly Consistency2 of 4 quarters downOkay
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +5.9%Inventory ↓ -11.6%Inv. % of Rev. 13%
RevenueInventoryInv. % of Rev.
2.8b2.8b2.9b2.9b428m368m380m379m202320242025TTM15.6%13.3%13.3%13%
Ranks #31 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#29HCA Healthcare54#30Regeneron Pharmaceuticals54
#31Revvity (you)54
#32Biogen53#33Cencora53

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B Ratio
2026US$ 2.9bUS$ 237.6mUS$ 627.6mUS$ 558.1mUS$ -69.5mUS$ 1.0bUS$ 3.3bUS$ 572.2mUS$ 7.2bUS$ 2.3bUS$ 1.3bUS$ 12.0bUS$ 4.8bUS$ 378.5m-3%8%0.5×1.8×3.6×13%---
2025US$ 2.9bUS$ 241.2mUS$ 582.9mUS$ 509.4mUS$ -73.5mUS$ 919.9mUS$ 3.4bUS$ 588.8mUS$ 7.3bUS$ 2.2bUS$ 1.3bUS$ 12.2bUS$ 4.9bUS$ 379.5mUS$ 28.0m3%8%0.5×1.7×3.9×14%0%45.6×1.5×
2024US$ 2.8bUS$ 270.4mUS$ 628.3mUS$ 541.7mUS$ -86.6mUS$ 1.2bUS$ 3.3bUS$ 0.2mUS$ 7.7bUS$ 2.3bUS$ 653.1mUS$ 12.4bUS$ 4.7bUS$ 367.6mUS$ 28.0m4%10%0.4×3.6×4.3×13%0%50.4×1.8×
2023US$ 2.8bUS$ 693.1mUS$ 91.3mUS$ 9.9mUS$ -81.4mUS$ 913.2mUS$ 4.1bUS$ 721.9mUS$ 7.9bUS$ 3.0bUS$ 1.5bUS$ 13.6bUS$ 5.7bUS$ 428.1mUS$ 28.0m9%25%0.5×2.1×2.9×5%0%19.3×1.7×